Literature DB >> 9836470

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

M Adams, A H Calvert, J Carmichael, P I Clark, R E Coleman, H M Earl, C J Gallagher, T S Ganesan, M E Gore, J D Graham, P G Harper, G C Jayson, S B Kaye, J A Ledermann, R J Osborne, T J Perren, C J Poole, J A Radford, G J Rustin, M L Slevin, J F Smyth, H Thomas, P M Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836470      PMCID： PMC2063222          DOI： 10.1038/bjc.1998.699

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson
Journal:  Gynecol Oncol       Date:  1990-02       Impact factor: 5.482

Review 2.  Advanced epithelial ovarian cancer: 1993 consensus statements.

Authors:  D G Allen; J Baak; D Belpomme; J S Berek; K Bertelsen; W W ten Bokkel Huinink; M E van der Burg; A H Calvert; P F Conte; J Dauplat
Journal:  Ann Oncol       Date:  1993       Impact factor: 32.976

3.  Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.

Authors:  V L Seewaldt; B E Greer; J M Cain; D C Figge; H K Tamimi; W S Brown; S A Miller
Journal:  Am J Obstet Gynecol       Date:  1994-06       Impact factor: 8.661

4.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  J T Thigpen; J A Blessing; H Ball; S J Hummel; R J Barrett
Journal:  J Clin Oncol       Date:  1994-09       Impact factor: 44.544

5.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544

6.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

7.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

Authors:  M Markman; R Rothman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadrones; J L Lewis
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

8.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

Authors:  G Blackledge; F Lawton; C Redman; K Kelly
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Management of ovarian cancer: referral to a multidisciplinary team matters.

Authors:  E J Junor; D J Hole; C R Gillis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

10.  Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

Authors:  M E Gore; V Levy; G Rustin; T Perren; A H Calvert; H Earl; J M Thompson
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640
View more
  12 in total

1.  Treatment guidelines in ovarian cancer.

Authors:  A Poveda Velasco; A Casado Herráez; A Cervantes Ruipérez; D Gallardo Rincón; E García García; A González Martín; G López García; C Mendiola Fernández; B Ojeda González
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

Review 2.  Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  New developments and approaches in the platinum arena.

Authors:  I Judson; L R Kelland
Journal:  Drugs       Date:  2000       Impact factor: 9.546

4.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

5.  SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease.

Authors:  Gabriele Calaminus; Rolf Kortmann; Jennifer Worch; James C Nicholson; Claire Alapetite; Maria Luisa Garrè; Catherine Patte; Umberto Ricardi; Frank Saran; Didier Frappaz
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

6.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

7.  Chemotherapy for ovarian cancer--trials, controversies and funding.

Authors:  R E Hawkins
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

8.  GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

Authors:  A González Martín; A Redondo; M Jurado; A De Juan; I Romero; I Bover; J M Del Campo; A Cervantes; Y García; J A López-Guerrero; C Mendiola; J Palacios; M J Rubio; A Poveda Velasco
Journal:  Clin Transl Oncol       Date:  2013-03-07       Impact factor: 3.405

9.  A longitudinal investigation of psychological morbidity in patients with ovarian cancer.

Authors:  V Gonçalves; G Jayson; N Tarrier
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

10.  Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

Authors:  B Gronlund; H H Hansen; C Høgdall; E V S Høgdall; S A Engelholm
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.